The Filings Report

Regeneron Pharmaceuticals Inc

REGNNasdaqCIK 872589Healthcare / Drug Manufacturersfiscal year ends December69 quarters since 2009

Revenue, Q2 FY2026
$4.3B
+16.7% on Q2 FY2025
Net income
$1.3B
−6.8% on Q2 FY2025
Free cash flow
$573M
−38.1% on Q2 FY2025
Diluted EPS
$12.23
−4.5% on Q2 FY2025
Revenue, TTM
$15.5B
trailing four quarters
Net margin, TTM
27.9%
net income $4.3B
Free cash flow, TTM
$3.8B
$4.7B less $921M capex
Cash and equivalents
$2.5B
long-term debt $2.0B, Jun 30, 2026
Shares, 12-month change
—
— shares, Jun 30, 2026
Buybacks, TTM
$3.3B
no yield
Dividends, TTM
$379M
no yield
Market value
—
at the close, buybacks

Latest quarter Q2 FY2026, filed July 30, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Regeneron Pharmaceuticals Inc reported revenue of $4.3B, +16.7% on Q2 FY2025, and net income of $1.3B (−6.8%). Operating margin was 30.1%. Free cash flow, operating cash flow less capital expenditures, was $573M ($813M less $240M). Diluted earnings per share were $12.23.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of July 30, 2026.

Revenue and net incomeRevenueNet income
$0$2B$4B$6BQ3'22, Revenue: $2.9BQ3'22, Net income: $1.3BQ3'22Q4'22, Revenue: $3.4BQ4'22, Net income: $1.2BQ4'22Q1'23, Revenue: $3.2BQ1'23, Net income: $818MQ1'23Q2'23, Revenue: $3.2BQ2'23, Net income: $968MQ2'23Q3'23, Revenue: $3.4BQ3'23, Net income: $1.0BQ3'23Q4'23, Revenue: $3.4BQ4'23, Net income: $1.2BQ4'23Q1'24, Revenue: $3.1BQ1'24, Net income: $722MQ1'24Q2'24, Revenue: $3.5BQ2'24, Net income: $1.4BQ2'24Q3'24, Revenue: $3.7BQ3'24, Net income: $1.3BQ3'24Q4'24, Revenue: $3.8BQ4'24, Net income: $918MQ4'24Q1'25, Revenue: $3.0BQ1'25, Net income: $809MQ1'25Q2'25, Revenue: $3.7BQ2'25, Net income: $1.4BQ2'25Q3'25, Revenue: $3.8BQ3'25, Net income: $1.5BQ3'25Q4'25, Revenue: $3.9BQ4'25, Net income: $845MQ4'25Q1'26, Revenue: $3.6BQ1'26, Net income: $727MQ1'26Q2'26, Revenue: $4.3BQ2'26, Net income: $1.3BQ2'26$0$2B$4B$6BQ3'22, Revenue: $2.9BQ3'22, Net income: $1.3BQ4'22, Revenue: $3.4BQ4'22, Net income: $1.2BQ4'22Q1'23, Revenue: $3.2BQ1'23, Net income: $818MQ2'23, Revenue: $3.2BQ2'23, Net income: $968MQ2'23Q3'23, Revenue: $3.4BQ3'23, Net income: $1.0BQ4'23, Revenue: $3.4BQ4'23, Net income: $1.2BQ4'23Q1'24, Revenue: $3.1BQ1'24, Net income: $722MQ2'24, Revenue: $3.5BQ2'24, Net income: $1.4BQ2'24Q3'24, Revenue: $3.7BQ3'24, Net income: $1.3BQ4'24, Revenue: $3.8BQ4'24, Net income: $918MQ4'24Q1'25, Revenue: $3.0BQ1'25, Net income: $809MQ2'25, Revenue: $3.7BQ2'25, Net income: $1.4BQ2'25Q3'25, Revenue: $3.8BQ3'25, Net income: $1.5BQ4'25, Revenue: $3.9BQ4'25, Net income: $845MQ4'25Q1'26, Revenue: $3.6BQ1'26, Net income: $727MQ2'26, Revenue: $4.3BQ2'26, Net income: $1.3BQ2'26

Net income losses drawn in red.

Free cash flow
$0$500M$1.0B$1.5B$2.0BQ3'22, Free cash flow: $486MQ3'22Q4'22, Free cash flow: $1.6BQ4'22Q1'23, Free cash flow: $1.2BQ1'23Q2'23, Free cash flow: $909MQ2'23Q3'23, Free cash flow: $938MQ3'23Q4'23, Free cash flow: $838MQ4'23Q1'24, Free cash flow: $1.4BQ1'24Q2'24, Free cash flow: $174MQ2'24Q3'24, Free cash flow: $1.0BQ3'24Q4'24, Free cash flow: $1.1BQ4'24Q1'25, Free cash flow: $816MQ1'25Q2'25, Free cash flow: $925MQ2'25Q3'25, Free cash flow: $1.4BQ3'25Q4'25, Free cash flow: $922MQ4'25Q1'26, Free cash flow: $848MQ1'26Q2'26, Free cash flow: $573MQ2'26$0$500M$1.0B$1.5B$2.0BQ3'22, Free cash flow: $486MQ4'22, Free cash flow: $1.6BQ4'22Q1'23, Free cash flow: $1.2BQ2'23, Free cash flow: $909MQ2'23Q3'23, Free cash flow: $938MQ4'23, Free cash flow: $838MQ4'23Q1'24, Free cash flow: $1.4BQ2'24, Free cash flow: $174MQ2'24Q3'24, Free cash flow: $1.0BQ4'24, Free cash flow: $1.1BQ4'24Q1'25, Free cash flow: $816MQ2'25, Free cash flow: $925MQ2'25Q3'25, Free cash flow: $1.4BQ4'25, Free cash flow: $922MQ4'25Q1'26, Free cash flow: $848MQ2'26, Free cash flow: $573MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3B$4BQ3'22, Cash and equivalents: $3.5BQ3'22, Long-term debt: $2.0BQ3'22Q4'22, Cash and equivalents: $3.1BQ4'22, Long-term debt: $2.0BQ4'22Q1'23, Cash and equivalents: $3.9BQ1'23, Long-term debt: $2.0BQ1'23Q2'23, Cash and equivalents: $1.9BQ2'23, Long-term debt: $2.0BQ2'23Q3'23, Cash and equivalents: $2.2BQ3'23, Long-term debt: $2.0BQ3'23Q4'23, Cash and equivalents: $2.7BQ4'23, Long-term debt: $2.0BQ4'23Q1'24, Cash and equivalents: $2.6BQ1'24, Long-term debt: $2.0BQ1'24Q2'24, Cash and equivalents: $1.9BQ2'24, Long-term debt: $2.0BQ2'24Q3'24, Cash and equivalents: $2.0BQ3'24, Long-term debt: $2.0BQ3'24Q4'24, Cash and equivalents: $2.5BQ4'24, Long-term debt: $2.0BQ4'24Q1'25, Cash and equivalents: $3.1BQ1'25, Long-term debt: $2.0BQ1'25Q2'25, Cash and equivalents: $2.0BQ2'25, Long-term debt: $2.0BQ2'25Q3'25, Cash and equivalents: $2.5BQ3'25, Long-term debt: $2.0BQ3'25Q4'25, Cash and equivalents: $3.1BQ4'25, Long-term debt: $2.0BQ4'25Q1'26, Cash and equivalents: $3.0BQ1'26, Long-term debt: $2.0BQ1'26Q2'26, Cash and equivalents: $2.5BQ2'26, Long-term debt: $2.0BQ2'26$0$1B$2B$3B$4BQ3'22, Cash and equivalents: $3.5BQ3'22, Long-term debt: $2.0BQ4'22, Cash and equivalents: $3.1BQ4'22, Long-term debt: $2.0BQ4'22Q1'23, Cash and equivalents: $3.9BQ1'23, Long-term debt: $2.0BQ2'23, Cash and equivalents: $1.9BQ2'23, Long-term debt: $2.0BQ2'23Q3'23, Cash and equivalents: $2.2BQ3'23, Long-term debt: $2.0BQ4'23, Cash and equivalents: $2.7BQ4'23, Long-term debt: $2.0BQ4'23Q1'24, Cash and equivalents: $2.6BQ1'24, Long-term debt: $2.0BQ2'24, Cash and equivalents: $1.9BQ2'24, Long-term debt: $2.0BQ2'24Q3'24, Cash and equivalents: $2.0BQ3'24, Long-term debt: $2.0BQ4'24, Cash and equivalents: $2.5BQ4'24, Long-term debt: $2.0BQ4'24Q1'25, Cash and equivalents: $3.1BQ1'25, Long-term debt: $2.0BQ2'25, Cash and equivalents: $2.0BQ2'25, Long-term debt: $2.0BQ2'25Q3'25, Cash and equivalents: $2.5BQ3'25, Long-term debt: $2.0BQ4'25, Cash and equivalents: $3.1BQ4'25, Long-term debt: $2.0BQ4'25Q1'26, Cash and equivalents: $3.0BQ1'26, Long-term debt: $2.0BQ2'26, Cash and equivalents: $2.5BQ2'26, Long-term debt: $2.0BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Regeneron Pharmaceuticals Inc income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 4, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 5, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue4,2913,6053,8843,7543,6763,0293,7893,721+16.7%
Cost of revenue—————————
Gross profit—————————
Research and development1,6321,5441,6261,4751,4221,3271,4121,272+14.8%
Selling, general and administrative662648775658634633792714+4.4%
Operating income1,2946438801,0271,0805929901,180+19.8%
Other income (expense)234188164737439313(32)314−46.7%
Pretax income1,5288311,0441,7631,5199059581,493+0.6%
Income tax2311041993031279640152+81.7%
Net income1,2977278451,4601,3928099181,341−6.8%
Diluted EPS ($)12.236.75—13.6212.817.27—11.54−4.5%
Diluted shares (millions)106108—107109111—116—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Regeneron Pharmaceuticals Inc balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 4, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 5, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents2,4562,9633,1182,5061,9963,0902,4882,012+23.0%
Short-term investments5,5395,7915,4875,9375,4745,2596,5247,785+1.2%
Total current assets18,44618,20918,02217,98116,86017,57218,66119,334+9.4%
Total assets41,73140,86940,55940,16938,21937,54537,75937,442+9.2%
Total current liabilities5,5315,1084,3684,4253,6673,5673,9443,661+50.8%
Long-term debt1,9871,9861,9861,9861,9851,9851,9841,984+0.1%
Total liabilities10,0199,4459,3029,2128,2808,1588,4068,116+21.0%
Stockholders’ equity31,71131,42431,25730,95829,93929,38829,35429,326+5.9%
Shares outstanding (millions)—————————

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Regeneron Pharmaceuticals Inc cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 4, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 5, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow8131,0791,1711,6191,1441,0451,2631,291−29.0%
Capital expenditures240231249201219229200242+9.7%
Free cash flow (CFO − capex)5738489221,4179258161,0631,049−38.1%
Depreciation and amortization124123145137135127126122−8.4%
Share repurchases1,1697946726641,0621,041973735+10.2%
Dividends paid97989391939400+4.5%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 4, 2026.

Income statement

Regeneron Pharmaceuticals Inc income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 4, 2026FY2024ended Dec 31, 2024filed Feb 5, 2025FY2023ended Dec 31, 2023filed Feb 5, 2024FY2022ended Dec 31, 2022filed Feb 6, 2023FY2021ended Dec 31, 2021filed Feb 7, 2022FY2020ended Dec 31, 2020filed Feb 8, 2021FY2019ended Dec 31, 2019filed Feb 7, 2020FY2018ended Dec 31, 2018filed Feb 7, 2019FY2017ended Dec 31, 2017filed Feb 8, 2018FY2016ended Dec 31, 2016filed Feb 9, 2017FY2015ended Dec 31, 2015filed Feb 11, 2016FY2014ended Dec 31, 2014filed Feb 12, 2015FY2013ended Dec 31, 2013filed Feb 13, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 21, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed Jul 28, 2010FY2008ended Dec 31, 2008filed Jul 28, 2010
Revenue14,34314,20213,11712,17316,0728,4976,5585,1465,8724,8604,1042,8202,1051,378446459379238
Cost of revenue——————403238——————————
Gross profit——————————————————
Research and development5,8505,1324,4393,5932,8602,6472,4501,4692,0752,0521,6211,271860626530489399275
Selling, general and administrative2,7002,9542,6312,1161,8251,3461,3421,1271,3201,178839519346211117655349
Operating income3,5783,9914,0474,7398,9473,5772,2102,5342,0801,3311,252824743458(205)(97)(74)(86)
Other income (expense)1,65378915212037923421919(1)(1)(27)(63)(47)(43)(18)(7)29
Pretax income5,2314,7804,1994,8599,3263,8102,4292,5542,0791,3301,225761696414(223)(104)(72)(77)
Income tax7263672465201,251297313109880434589423283(336)(1)0(4)2
Net income4,5054,4133,9544,3388,0753,5132,1162,4441,199896636338414750(222)(104)(68)(79)
Diluted EPS ($)41.4838.3434.7738.2271.9730.5218.4621.2910.347.705.522.983.726.75(2.45)(1.26)——
Diluted shares (millions)1091151141141121151151151161161151131111159183——

Balance sheet

Regeneron Pharmaceuticals Inc balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 4, 2026FY2024ended Dec 31, 2024filed Feb 5, 2025FY2023ended Dec 31, 2023filed Feb 5, 2024FY2022ended Dec 31, 2022filed Feb 6, 2023FY2021ended Dec 31, 2021filed Feb 7, 2022FY2020ended Dec 31, 2020filed Feb 8, 2021FY2019ended Dec 31, 2019filed Feb 7, 2020FY2018ended Dec 31, 2018filed Feb 7, 2019FY2017ended Dec 31, 2017filed Feb 8, 2018FY2016ended Dec 31, 2016filed Feb 9, 2017FY2015ended Dec 31, 2015filed Feb 11, 2016FY2014ended Dec 31, 2014filed Feb 12, 2015FY2013ended Dec 31, 2013filed Feb 13, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 21, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed Jul 28, 2010FY2008ended Dec 31, 2008filed Jul 28, 2010
Cash and equivalents3,1182,4882,7303,1062,8862,1941,6181,468813535809649536230484113207248
Short-term investments5,4876,5248,1154,6362,8091,3931,5971,3425975032362521587843137134—
Total current assets18,02218,66119,47915,88414,0159,7797,6896,4484,3353,1802,9152,0851,7971,206666358426—
Total assets40,55937,75933,08029,21525,43517,16314,80511,7358,7646,9735,6093,8382,9512,0801,3241,089741—
Total current liabilities4,3683,9443,4233,1413,9332,6972,0971,4431,1361,24181165529916414810994—
Long-term debt1,9861,9841,9831,9811,9801,9790———————————
Total liabilities9,3028,4067,1076,5516,6666,1383,7162,9772,6202,5241,9541,287999835838562344—
Stockholders’ equity31,25729,35425,97322,66418,76911,02511,0908,7576,1444,4493,6552,5501,9651,257486528397422
Shares outstanding (millions)——————————————9288——

Cash flow statement

Regeneron Pharmaceuticals Inc cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 4, 2026FY2024ended Dec 31, 2024filed Feb 5, 2025FY2023ended Dec 31, 2023filed Feb 5, 2024FY2022ended Dec 31, 2022filed Feb 6, 2023FY2021ended Dec 31, 2021filed Feb 7, 2022FY2020ended Dec 31, 2020filed Feb 8, 2021FY2019ended Dec 31, 2019filed Feb 7, 2020FY2018ended Dec 31, 2018filed Feb 7, 2019FY2017ended Dec 31, 2017filed Feb 8, 2018FY2016ended Dec 31, 2016filed Feb 9, 2017FY2015ended Dec 31, 2015filed Feb 11, 2016FY2014ended Dec 31, 2014filed Feb 12, 2015FY2013ended Dec 31, 2013filed Feb 13, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 21, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed Jul 28, 2010FY2008ended Dec 31, 2008filed Jul 28, 2010
Operating cash flow4,9794,4214,5945,0157,0812,6182,4302,1951,3071,4861,331752589(75)(142)99(70)(89)
Capital expenditures89875671959055261543038327351267833315649571009735
Free cash flow (CFO − capex)4,0813,6653,8754,4256,5292,0042,0001,8121,035974653419432(124)(199)0(167)(124)
Depreciation and amortization5444834213412862362101481461057553413731201411
Share repurchases3,4392,6032,2352,0831,6455,847276400————————
Dividends paid37000———————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$7M
32 sales by 4 insiders; officers and directors $7M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$12M
105 sales by 7 insiders; officers and directors $12M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-16$753.76$5K51,974Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-135$755.91$26K51,939Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-116$757.68$12K51,923Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-124$758.16$18K51,899Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-114$759.96$11K51,885Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-174$760.65$56K51,811Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-127$761.36$21K51,784Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-155$762.57$42K51,729Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-125$763.76$19K51,704Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1219$764.40$167K51,485Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1271$765.39$207K51,214Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1279$766.47$214K50,935Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1192$767.39$147K50,743Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1105$768.33$81K50,638Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1127$769.30$98K50,511Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-112$770.20$9K50,499Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1283$771.56$218K50,216Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1211$772.56$163K50,005Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1224$773.40$173K49,781Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1121$774.48$94K49,660Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1376$775.46$292K49,284Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-166$776.31$51K49,218Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-138$777.76$30K49,180Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1454$778.64$354K48,726Oct 15, 2026
Oct 14, 2026Murphy Andrew JCo-Chief Scientific Officeropen-market sale10b5-1380$779.59$296K48,346Oct 15, 2026

Full insider history for Regeneron Pharmaceuticals Inc, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
REGENERON PHARMACEUTICALS, INC., CIK 872589 on EDGAR
Extract generated
August 27, 2026
Withheld
2 line-years whose four quarters do not sum to the filed year: net income FY2013, revenue FY2018
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2018, other income FY2018
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/REGN.json